ALLERGAN USA, INC. for ALLERGAN USA, INC.

Taxation/Internal Revenue Code TAX

Tax codes that ensure investment in research & development of novel treatments for patients. Potential modifications and technical corrections to Tax Cuts and Jobs Act of 2017 (P.L. 115-97).

Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent that policy affects the tax treatment of its subsidiaries, foreign and domestic.

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Copyright/Patent/Trademark CPT

Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Patent & Trademark Office (PTO)

Health Issues HCR

Access to appropriate mental health care treatments across the U.S. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Patent & Trademark Office (PTO)

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).

Contacted: HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Bills named: H.R. 3204 (115th)

Pharmacy PHA

Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug compounding and the Drug Quality and Security Act of 2013. Drug importation/counterfeit drugs.

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Medical/Disease Research/Clinical Labs MED

Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.

Contacted: Food & Drug Administration (FDA); SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.

Contacted: Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO)